Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction

Author:

Tsuda Takuma1,Takefuji Mikito1ORCID,Wettschureck Nina2,Kotani Kazuhiko3,Morimoto Ryota1,Okumura Takahiro1,Kaur Harmandeep2,Eguchi Shunsuke1,Sakaguchi Teruhiro1,Ishihama Sohta1,Kikuchi Ryosuke4,Unno Kazumasa1,Matsushita Kunihiro5,Ishikawa Shizukiyo3,Offermanns Stefan2,Murohara Toyoaki1

Affiliation:

1. Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan

2. Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany

3. Center for Community Medicine, Jichi Medical University, Shimotsuke, Japan

4. Department of Medical Technique, Nagoya University Hospital, Nagoya, Japan

5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Abstract

Heart failure occurs when the heart is unable to effectively pump blood and maintain tissue perfusion. Despite numerous therapeutic advancements over previous decades, the prognosis of patients with chronic heart failure remains poor, emphasizing the need to identify additional pathophysiological factors. Here, we show that corticotropin releasing hormone receptor 2 (Crhr2) is a G protein–coupled receptor highly expressed in cardiomyocytes and continuous infusion of the Crhr2 agonist, urocortin 2 (Ucn2), reduced left ventricular ejection fraction in mice. Moreover, plasma Ucn2 levels were 7.5-fold higher in patients with heart failure compared to those in healthy controls. Additionally, cardiomyocyte-specific deletion of Crhr2 protected mice from pressure overload-induced cardiac dysfunction. Mice treated with a Crhr2 antagonist lost maladaptive 3′-5′-cyclic adenosine monophosphate (cAMP)–dependent signaling and did not develop heart failure in response to overload. Collectively, our results indicate that constitutive Crhr2 activation causes cardiac dysfunction and suggests that Crhr2 blockade is a promising therapeutic strategy for patients with chronic heart failure.

Funder

Ministry of Education, Culture, Sports, Science and Technology

Takeda Science Foundation

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3